# Diabetes Research Hub — Monitor Report
**Date:** 2026-04-09
**Run type:** Automated scheduled scan
**Previous report:** monitor_report_2026-04-08.md

---

## File System Status

Core script outputs are fresh (all generated within the last ~24 hours by the overnight cron):

| File | Last Modified | Status |
|---|---|---|
| `hub_monitor_report.md` | 2026-04-09 02:05 | FRESH |
| `hub_monitor_state.json` | 2026-04-09 02:05 | FRESH |
| `clinical_trials_latest.json` | 2026-04-09 02:04 | FRESH |
| `clinical_trials_snapshot_2026-04-09.json` | 2026-04-09 02:04 | FRESH |
| `clinical_trials_summary.md` | 2026-04-09 02:04 | FRESH |
| `pubmed_recent_latest.json` | 2026-04-09 02:05 | FRESH |
| `pubmed_recent_snapshot_2026-04-09.json` | 2026-04-09 02:05 | FRESH |
| `pubmed_recent_summary.md` | 2026-04-09 02:05 | FRESH |
| `literature_gap_data.json` | 2026-04-03 09:31 | **STALE (6 days)** |
| `literature_gap_report.md` | 2026-04-08 03:07 | FRESH |
| `agent_state.json` | 2026-04-08 03:07 | FRESH |
| `citation_validation.json` | 2026-04-08 03:08 | FRESH |

**Flags from hub_monitor.py:** 355 result files older than 14 days may need refresh (mostly historical snapshots — no action required unless a specific study depends on them). The underlying `literature_gap_data.json` is 6 days old; `literature_gap_report.md` was regenerated 2026-04-08 but against the older data — consider re-running the gap analysis script this week.

Hub totals: 687 files tracked; 3 new files and 28 modified files in the last 24h (driven by yesterday's agent refresh of dashboards and evidence indices).

---

## Clinical Trial Changes (2026-04-08 → 2026-04-09)

**Headline:** 757 unique trials tracked (151 T1D Cure/Cell Therapy, 71 T1D Immunotherapy, 137 T2D Phase 2–3, 220 Diabetes Tech, 253 Recently Completed w/ Results). 261 currently RECRUITING, 116 Phase 3, 44 Phase-3-and-RECRUITING.

**New trials (2):**
- **NCT07518004** — ROME GS System Study: prospective multicenter evaluation of accuracy and safety of a glucose sensor system (NA / RECRUITING). Diabetes Technology category.
- **NCT07517770** — Effectiveness of AI Bolus Priming added to an existing fully automated insulin delivery system (NA / NOT_YET_RECRUITING). Diabetes Technology / Closed-Loop AI category.

**Status changes (1):**
- **NCT07112872** — "A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide": **RECRUITING → ACTIVE_NOT_RECRUITING**. Roche-sponsored GLP-1 comparator trial has finished enrollment; results watch begins. Worth a tracker entry.

**Removed trials:** 0
**New results posted:** 0

**Key-organization trial counts (unchanged vs. yesterday):**
- Eli Lilly and Company: 27
- Novo Nordisk A/S: 23
- Vertex Pharmaceuticals: 3
- Sana Biotechnology: 0 (no active diabetes-indication trials currently indexed)

No Phase-3-results drops today. No new trials from the four priority sponsors today.

---

## PubMed Highlights (2026-04-08 → 2026-04-09)

Snapshot diff: **26 new papers**, 28 dropped from rolling 30-day window. Total in window: 128 unique papers across 15 alert domains.

**Volume trend signals:** HIGH ACTIVITY in Diabetes AI/ML (173), T2D GLP-1 New (147), Diabetes Microbiome (146), Diabetes Biomarker (124), Diabetes Health Equity (67). LOW activity in Diabetes Epigenetics (6), Diabetes Drug Repurpose (5), LADA New Research (4) — LADA remains chronically under-published, consistent with our Tier 1 gap hypothesis.

**Cross-domain new papers (4) — highest priority to review:**

1. **PMID 41947261** — *Integrative multi-omics suggests core gene dysregulation of histidine metabolism in diabetic kidney [disease]*
   Domains: Diabetes Biomarker × Diabetes Multi-Omics. Potentially relevant to the multi-omics biomarker discovery stream.

2. **PMID 41947478** — *Astragaloside IV Exhibited Antidiabetic Effects by Improving Glucose Metabolism, Repairing Damaged [islets?]*
   Domains: T2D Remission × Diabetes Microbiome. Preclinical; evidence Level V under the Doctrine. Worth noting but not tracker-worthy alone.

3. **PMID 41950248** — *MaxGRNet: A multi-axis vision transformer with improved generalization for eye disease classification*
   Domains: Diabetes AI/ML × Diabetes Complications New. Methods paper on DR screening.

4. **PMID 41950426** — *Large-scale AI analysis reveals missed opportunities in albuminuria testing and disease-modifying therapy [use]*
   Domains: Diabetes AI/ML × Diabetes Microbiome (likely mis-tag; real overlap is AI/ML × Health Equity / Care Gaps). **High interest** — directly supports a "missed care" narrative that aligns with our Health Equity Tier-1 theme.

**Key-therapy watchlist:** No direct mentions of zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, or teplizumab in the 26 new papers' titles/snippets today. (Orforglipron news is in the press/FDA channel — see Breaking News below.)

---

## Gap Analysis Summary

Source: `literature_gap_data.json` (2026-04-03). **Recommendation: re-run `project1_literature_gap_analysis.py` — data is 6 days old.**

**Top 5 under-researched intersections** (ranked by expected joint publications where actual pair_count = 0, i.e. the largest "missing" literatures):

| Rank | Domain 1 | Domain 2 | Expected | Actual |
|---|---|---|---|---|
| 1 | GWAS / Polygenic | Closed Loop / AP | ~2,985 | 0 |
| 2 | Drug Repurposing | CGM Technology | ~1,877 | 0 |
| 3 | Treg / CAR-T | Neuropathy | ~1,615 | 0 |
| 4 | Beta Cell Regen | Health Equity | ~1,603 | 0 |
| 5 | Treg / CAR-T | Health Equity | ~1,272 | 0 |

**Alignment with Tier-1 doctrine contribution areas** (Health Equity, Drug Repurposing, LADA, Islet Transplant):

- **Beta Cell Regen × Health Equity** (rank 4) and **Treg/CAR-T × Health Equity** (rank 5) both directly target the Tier-1 equity theme — genuine, actionable whitespace flagged as BRONZE-validated in the existing report.
- **Drug Repurposing × CGM Technology** (rank 2) is cross-domain and plausibly meaningful (e.g., repurposing candidates that modulate glucose variability could be studied using CGM-derived phenotypes as endpoints).
- **Treg / CAR-T × Neuropathy** (rank 3) is intriguing but methodologically distant; verify before investing.
- **GWAS × Closed-Loop AP** (rank 1) is almost certainly methodologically distinct (genomics vs. device engineering) — flagged as such in the enriched gap report and should be deprioritized.

See `literature_gap_report.md` ranks 1–15 for additional BRONZE-validated gap candidates (notably: Islet Transplant × Drug Repurposing, Gene Therapy × LADA, Glucokinase × LADA, Drug Repurposing × LADA, Health Equity × LADA — the LADA pairings are unusually concentrated and mutually reinforce our Tier-1 LADA bet).

---

## Breaking News (Web Scan, Last ~7 Days)

Two items rise above routine noise:

1. **FDA approved Foundayo (orforglipron) — Eli Lilly** (announced April 1, 2026). First oral small-molecule GLP-1 RA approved for chronic weight management in the US; no food/water timing restrictions. This is a **major milestone for the oral GLP-1 class** and directly relevant to our T2D GLP-1 New alert domain. Lilly has filed in 40+ countries. Action: add to tracker with Evidence Level I (FDA approval based on Phase 3 ACHIEVE program).

2. **Tzield (teplizumab) pediatric age-expansion PDUFA date: April 29, 2026** (two weeks out). Priority-review sBLA to extend indication from ≥8 years down to ≥1 year for stage 2 T1D. Already covered in `teplizumab_sNDA_decision_prep.md` — worth re-reading that prep doc before the decision and setting a reminder. Action: flag 2026-04-29 on the tracker.

Other items (generic dapagliflozin/metformin approval to Lupin 2026-04-08; ProKidney rilparencel Phase 2 eGFR slope data; Novo amycretin Phase 3 setup) are relevant context but not action-worthy for the hub this week.

Nothing found on zimislecel Phase 3 topline, retatrutide Phase 3 readouts, or CagriSema updates in the last 7 days.

---

## Recommended Actions

Priority-ordered, concrete next steps:

1. **Re-run the gap analysis script.** `literature_gap_data.json` is 6 days old; the interpreted report was regenerated yesterday against stale underlying data. Run: `python project1_literature_gap_analysis.py`.

2. **Update `Diabetes_Research_Tracker.xlsx`** with:
   - FDA approval of **Foundayo (orforglipron)** on 2026-04-01 (Evidence Level I).
   - Status change for **NCT07112872** (Roche RO7795081 vs semaglutide) — RECRUITING → ACTIVE_NOT_RECRUITING; begin results-watch.
   - Two new technology trials (**NCT07518004** ROME GS, **NCT07517770** AI Bolus Priming) if they fit the Closed-Loop / CGM subcategory being tracked.
   - Calendar flag: **Tzield pediatric PDUFA 2026-04-29**.

3. **Review cross-domain PubMed paper PMID 41950426** ("Large-scale AI analysis reveals missed opportunities in albuminuria testing…") — likely directly supportive of a Health-Equity / care-gap narrative under our Tier-1 theme. Pull the full text and evaluate citation-worthiness.

4. **Review PMID 41947261** (multi-omics histidine metabolism in diabetic kidney disease) for the biomarker stream — potentially tracker-worthy depending on cohort size and validation.

5. **Read `teplizumab_sNDA_decision_prep.md`** before the 2026-04-29 PDUFA date and prepare a short contribution note if the expansion is approved.

6. **No action** on the 355 stale file flag from hub_monitor — these are historical snapshots and intentional.

---

## Evidence Levels Applied

Per `RESEARCH_DOCTRINE.md`:
- **Level I (Highest):** FDA approval — Foundayo/orforglipron.
- **Level II:** Phase 3 clinical trial status changes — NCT07112872 (reporting not yet released).
- **Level V (Preclinical):** PMID 41947478 (Astragaloside IV, animal/cell).
- **Bronze (gap analysis):** All literature gap rankings — single analytical source, require expert confirmation before attribution.

No new tracker claims were generated by this run (review-only run, per scheduled-task rules).

---
*Generated by automated hub monitor — 2026-04-09*
*Source files read: hub_monitor_report.md, clinical_trials_latest.json, clinical_trials_snapshot_2026-04-08.json, clinical_trials_summary.md, pubmed_recent_latest.json, pubmed_recent_summary.md, literature_gap_data.json, literature_gap_report.md*
